All News
Telemedicine Studies: A Trainee’s Perspective
The shift from face-to-face consultations to telemedicine has been immense for clinicians and patients. Given the numerous challenges and nuances in practising telemedicine, it is apt that ACR 2020 has been packed with abstracts and presentations on this topic.
Read Article
Summary of #ACR20 part A:
- HCQ is not a problem in rheumatic dz pts in terms of causing QTc prolongation
- Anti-phospholipid ab are found in a majority of hospitalized COVID19 pts — the most prevalent of which were anti-PST abs that are not in the of criteria for APS
@rheumnow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
What was the effect of COVID-19 in axSpA patients? From @rheum_cat In the early phase of COVID-19 there was a higher levels of stress and anxiety leading to higher BASDAI scores @RheumNow #ACR20 Abstr#1884
Dr. Antoni Chan synovialjoints ( View Tweet)
Tocilizumab NOT effective in preventing mechanical ventilation or death in moderately ill COVID-19 pts.
Double-blind, Placebo, RCT (n=243)
@RheumNow #ACR20 Abs#L07 #ACRbest https://t.co/juSQRCnTeD
Robert B Chao, MD doctorRBC ( View Tweet)
Does IL-6 blockade prevent mechanical ventilation or death in #COVID19? MGH study by Dr. Stone Abst#L07 graph shows no benefit @RheumNow #ACR20 https://t.co/DHfHYJCkod
Eric Dein ejdein1 ( View Tweet)
Dr. N Nikolov #FDA reviews role for rheum meds in #COVID19 and outlines guidance for trial design for CV19 therapeutics #ACR20 @rheumnow https://t.co/0oPvBN5mgF
k dao KDAO2011 ( View Tweet)
We need to work together with our patients to ensure medication adherence during this pandemic.
1⃣30% of 734 pts on DMARDs changed their med use during COVID
2⃣Med change without physician guidance
3⃣Changes resulted in ⬆️steroid use
@RheumNow #ACR20 Abs#L05 https://t.co/n18zqed4wC
Robert B Chao, MD doctorRBC ( View Tweet)
@rheumNow #ACR20 #ABSL02 registry data: Pts on biologics more likely to Shield at Home during COVID 19 as opposed to non-biologic or no systemic Rx at all. Such stringent mitigation tactics may contribute to the reported lower risk of adverse COVID-19 outcomes in biologics Pts
Olga Petryna DrPetryna ( View Tweet)
@uptoTate @RheumNow It is only when I started working more closely with our rheum team to look at improving services did I realise how high no-shows are ! We have a 2yr waiting list so these appts are like gold dust. Unfortunately telemedicine not a viable option for your 1st rheum appt.
Wendy Costello wendycostello2 ( View Tweet)
Frequency and Anatomic Distribution of MRI Lesions in the Sacroiliac Joints of Healthy Subjects and Patients with Spondyloarthritis. Dr Hecquet. #ACR20 @RheumNow BME was seen in 65% patients with Spa and in 20% without spondyloarthritis predominantly in the antero-middle quadrant https://t.co/OUYz2FQ5Yp
Sole RetamozoSole ( View Tweet)
Important work by Dr. Winthrop on influenza AEs in Tofacinitib patients - similar among 5mg/10mg BID, only 2 deaths/~500 cases, both with H1N1 and co-morbid RFs. Abst#L04 @RheumNow #ACR20 https://t.co/7MZYGv8W3i
Eric Dein ejdein1 ( View Tweet)
Do you have a problem with no-shows? #ABS1584 discusses telemedicine and care access during COVID-19. Case Western observed a 0% cancellation rate, <10% no-show rate, & 90% of scheduled telemed visits completed during COVID-19. #ACR20 #ACRbest @RheumNow https://t.co/uxzpfELDBG https://t.co/U2qrOTJZOq
Dr. Rachel Tate uptoTate ( View Tweet)
Abst#L01. Pt is on MTX/ADA for RA and asks you about their COVID risk. What do you counsel your patient? #ACR20 @RheumNow.
Eric Dein ejdein1 ( View Tweet)
I just reviewed the #ACR20 talk regarding vaccination. Highly recommended/timely given data released from Pfizer today regarding the COVID-19 vaccine trial. @RheumNow
Pfizer’s Early Data Shows Vaccine Is More Than 90% Effective - The New York Times https://t.co/Fb5ZepCBeJ
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Bermas presented #GRA data on 14 rheumatic Pregnant women w/ COVID-19 w/ good outcomes (4 hospitalized & no deaths) but MMWR just reported preg COVID may have worse outcomes. https://t.co/6SD6Rzbxwx https://t.co/C4QS23axfN
Links:
Dr. John Cush RheumNow ( View Tweet)
The @rheum_covid experience with patients with rheumatic disease who are *pregnant* and get COVID-19 is being presented by Bonnie Bermas from UTSouthwestern #ACR20 Sunday 3pm Eastern https://t.co/eeKqMXgpFx
Dr Philip Robinson philipcrobinson ( View Tweet)
A Convergence of Ideas: COVID19 and ACR by Dr. Kathryn Dao (@KDAO2011)
#ACR20
https://t.co/0Rxv9GjOkw https://t.co/2uOiOZfSfM
Links:
Dr. John Cush RheumNow ( View Tweet)
@RetamozoSole @RheumNow @Reumaclinic @MAS_Clinic @hospitalclinic #ACR20 Thanks for sharing! but our data show that patients under anti-Cytokine therapy in monotherapy at baseline (specifically anti-IL6 -IL12/23 and -IL17) or under JAKinh were ⬇️LESS likely to be admitted (OR 0.15; 95% CI 0.03-0.66; p=0.012)
📍Limitations: small number of pts https://t.co/zeLzrNLeDQ
Juan Camilo Sarmiento-Monroy jcsam25 ( View Tweet)
Awesome #COVID19 vaccine round table tonight at #ACR20 @LCalabreseDO @ACRheum @HealioRheum @RheumNow https://t.co/a6jwDHc95v
Cassandra Calabrese CCalabreseDO ( View Tweet)
Dan Barouch: The #COVID19 has advantage of known spike protein which is a natural target for vaccination. HIV by contrast does not have such an obvious target. #ACR20 @RheumNow
Eric Dein ejdein1 ( View Tweet)
